Free Trial
NASDAQ:ELAB

Elevai Labs (ELAB) Stock Price, News & Analysis

Elevai Labs logo
$0.02 0.00 (0.00%)
(As of 11/21/2024 ET)

About Elevai Labs Stock (NASDAQ:ELAB)

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.35
52-Week Range
$0.02
$4.24
Volume
241.64 million shs
Average Volume
34.02 million shs
Market Capitalization
$420,362.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Elevai Labs Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
7th Percentile Overall Score

ELAB MarketRank™: 

Elevai Labs scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Elevai Labs.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevai Labs has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Elevai Labs' valuation and earnings.
  • Percentage of Shares Shorted

    56.82% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elevai Labs does not currently pay a dividend.

  • Dividend Growth

    Elevai Labs does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    56.82% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    24 people have searched for ELAB on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevai Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    37.00% of the stock of Elevai Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.22% of the stock of Elevai Labs is held by institutions.

  • Read more about Elevai Labs' insider trading history.
Receive ELAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter.

ELAB Stock News Headlines

CORRECTION - Elevai Labs Inc.
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Elevai Biosciences highlights past preclinical data on EL-32
See More Headlines

ELAB Stock Analysis - Frequently Asked Questions

Elevai Labs' stock was trading at $1.8282 at the beginning of the year. Since then, ELAB stock has decreased by 98.9% and is now trading at $0.0202.
View the best growth stocks for 2024 here
.

Elevai Labs (ELAB) raised $6 million in an IPO on Tuesday, November 21st 2023. The company issued 1,500,000 shares at $4.00 per share. Univest Securities served as the underwriter for the IPO.

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

Today
11/21/2024
Next Earnings (Estimated)
12/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELAB
Previous Symbol
NASDAQ:ELAB
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-4,300,000.00
Net Margins
-223.41%
Pretax Margin
-223.37%

Debt

Sales & Book Value

Annual Sales
$1.71 million
Book Value
$0.41 per share

Miscellaneous

Free Float
13,107,000
Market Cap
$424,524.00
Optionable
N/A
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:ELAB) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners